

NEUROSCIENCE MEDICINES

MARKETED PRODUCTS¹

Seroquel (quetiapine fumarate) is an atypical anti-psychotic drug. It is approved for the treatment of schizophrenia, bipolar mania and bipolar depression. Its overall clinical efficacy and tolerability profile helped make it the leading atypical anti-psychotic in the US.

Zomig (zolmitriptan) is for the treatment of migraine with or without aura.

Diprivan (propofol), an intravenous general anaesthetic, is used in the induction and maintenance of anaesthesia, light sedation for diagnostic procedures and for intensive care sedation.

Naropin (ropivacaine), with its safety and mobility profile, is the world's best-selling, long-acting local anaesthetic, replacing the previous standard treatment of bupivacaine.

Xylocaine (lidocaine) continues to be the world's most widely used short-acting local anaesthetic after more than 50 years on the market.

2007 IN BRIEF

- > **Seroquel sales up 15% to over \$4 billion.**
- > **Seroquel XR major depressive disorder and generalised anxiety disorder clinical study data presented for the first time. US and EU regulatory submissions planned in 2008.**
- > **Seroquel XR approved in nine countries, including the US, and progressed through the mutual recognition procedure in the EU, for acute and maintenance treatment of schizophrenia.**
- > **US regulatory submissions for Seroquel XR for the treatment of bipolar depression and bipolar mania.**
- > **AZD3480 entered Phase IIb testing in Alzheimer's disease and cognitive disorders in schizophrenia.**
- > **Patent infringement actions commenced against two generic drug manufacturers in the US following abbreviated new drug applications relating to Seroquel.**
- > **Numerous personal injury actions in the US and Canada involving Seroquel being defended vigorously.**

PERFORMANCE

	2007			2006			2005	2007 compared to 2006		2006 compared to 2005	
	Sales \$m	Growth underlying \$m	Growth due to exchange effects \$m	Sales \$m	Growth underlying \$m	Growth due to exchange effects \$m		Growth underlying %	Growth reported %	Growth underlying %	Growth reported %
Seroquel	4,027	526	85	3,416	655	-	2,761	15	18	24	24
Zomig	434	18	18	398	47	(1)	352	5	9	13	13
Diprivan	263	(53)	12	304	(62)	(3)	369	(17)	(13)	(17)	(18)
Local anaesthetics	557	(6)	34	529	24	(6)	511	(1)	5	5	4
Other	59	(1)	3	57	(8)	(1)	66	(2)	4	(12)	(14)
Total	5,340	484	152	4,704	656	(11)	4,059	10	14	16	16

PIPELINE

Compound	Mechanism	Areas under investigation	Phase			Estimated filing date	
			I	II	III	Europe	US
NCEs							
PN400	naproxen + esomeprazole	signs and symptoms of OA, RA, and AS	■	■	■	1H 2009	1H 2009
AZD3480	neuronal nicotinic receptor agonist	cognitive disorders in schizophrenia	■	■		2011	2011
AZD3480	neuronal nicotinic receptor agonist	Alzheimer's disease	■	■		2011	2011
AZD6765	NMDA receptor antagonist	depression	■	■			
AZD2327	enkephalinergic receptor modulator	anxiety and depression	■				
AZD5904	inhibitor of myeloperoxidase (MPO)	multiple sclerosis	■				
AZD3241	inhibitor of myeloperoxidase (MPO)	Parkinson's disease	■				
AZD0328	selective neuronal nicotinic receptor agonist	Alzheimer's disease	■				
AZD1940	CB receptor agonist	nociceptive and neuropathic pain	■				
AZD2624	NK receptor antagonist	schizophrenia	■				
AZD1386	vanilloid receptor antagonist	chronic nociceptive pain	■				
AZD2066	metabotropic glutamate receptors	chronic nociceptive pain	■				
AZD7325	GABA receptor subtype partial agonist	anxiety	■				
AZD6280	GABA receptor subtype partial agonist	anxiety	■				
TC-5619 (Targacept)	neuronal nicotinic receptor agonist	cognitive disorders in schizophrenia	■				
Line extensions							
Seroquel XR	D ₂ /5HT ₂ antagonist	schizophrenia	■	■	■	Approved	Launched
Seroquel	D ₂ /5HT ₂ antagonist	bipolar maintenance	■	■	■	2Q 2008	Filed
Seroquel	D ₂ /5HT ₂ antagonist	bipolar depression	■	■	■	1Q 2008	Launched
Seroquel XR	D ₂ /5HT ₂ antagonist	generalised anxiety disorder	■	■	■	4Q 2008	2Q 2008
Seroquel XR	D ₂ /5HT ₂ antagonist	major depressive disorder	■	■	■	3Q 2008	1Q 2008
Seroquel XR	D ₂ /5HT ₂ antagonist	bipolar mania	■	■	■	1Q 2008	Filed
Seroquel XR	D ₂ /5HT ₂ antagonist	bipolar depression	■	■	■	1Q 2008	Filed

For discontinued projects see page 30.

¹ In 2006, we sold our range of US branded anaesthetics and analgesic products to Abraxis BioScience, Inc.. These included Xylocaine™, Polocaine™, Naropin™, Nesacaine™, Sensorcaine™, Astramorph™, EMLA Cream™ and Diprivan™.